MyControl

MyControl

With our website MyControl, we hope to increase knowledge about obesity among the general public.

The site, which highlights causes, risks and the benefits of a long-term weight loss, places great focus on the brain’s role in developing and mastering the disease and, in addition to current treatment options, also addresses the importance of the right treatment. The website is available in Norwegian, Swedish, Danish & Finnish.

Obesity is as a chronic disease in which excess body fat has accumulated to an extent that it may have a negative effect on health.1 Obesity increases the likelihood of various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, osteoarthritis, and depression.2,3 People are generally considered obese when their body mass index (BMI), a measurement obtained by dividing a person’s weight by the square of the person’s height, is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight.1

In 2020, nearly 1 billion people world wide were living with obesity – in 2035 that number is expected to grow to 1.9 billion.4 15-23% of the Nordic population are obese and the cost of treating obesity-related complication are enormous.5

Unfortunately, physiological adaptations to weight loss favour weight regain. These changes include perturbations in the levels of circulating appetite-related hormones and energy homoeostasis, in addition to alterations in nutrient metabolism and subjective appetite. To maintain weight loss, individuals must adhere to behaviours that counteract physiological adaptations and other factors favouring weight regain. It is difficult to overcome physiology with behaviour, why medications, and sometimes surgery, are the best treatment alternatives for many patients.6

Navamedic contributes to obesity management by providing top of the line pharmaceutical treatment that can help patients lose weight and keep a lower weight. Navamedic also educates healthcare personnel in obesity management.


References:

  1. Obesity and overweight Fact sheet. WHO. January 2018. Retrieved 10 February 10, 2020.
  2. Haslam DW, James WP (October 2005). “Obesity”. Lancet (Review). 366 (9492): 1197–209. doi:10.1016/S0140-6736(05)67483-1. PMID 16198769.
  3. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG (March 2010). “Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies”. Archives of General Psychiatry. 67 (3): 220–9.
  4. Worldwide trends in underweightand obesity from 1990 to 2022. Lancet 2024 Feb 29:S0140-6736(23)02750-2.doi: 10.1016/S0140-6736(23)02750-2.
  5. Folkhälsomyndigheten https://www.folkhalsomyndigheten.se/livsvillkor-levnadsvanor/fysisk-aktivitet-och-matvanor/overvikt-och-fetma/
  6. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond) 201:39 (8)